Biological Modifiers (Etetrinate and Interferon Alfa 2a) in the Treatment of Refractory Cutaneous T-Cell Lymphoma-Reference-Cited by-同舟云学术

Biological Modifiers (Etetrinate and Interferon Alfa 2a) in the Treatment of Refractory Cutaneous T-Cell Lymphoma

Published:1996-02 Issue:1 Volume:11 Page:21-24
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Avilés Agustin,Guzmán Renaldo,García Edna L.,Díaz-Maqueo José C.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.1996.11.21

Reference9 articles.

1. Successful treatment of mycosis fungoides with the combination of etretinate and human recombinant interferon alfa-2a

2. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy.

3. The Therapeutic Role of Interferons and Monoclonal Antibodies in Cutaneous T-Cell Lymphomas

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017;European Journal of Cancer;2017-05

2. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome;Hematology;2015-12-05

3. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma;Hematology;2015-01-16

4. Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome;Lymphoma;2013

5. Biological therapy of B and T cell lymphoproliferative disorders;Principles of Cancer Biotherapy;2009